Northland Securities Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $16
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior (INDV) Receives a Buy From Craig-Hallum
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $16
Rodman & Renshaw Initiates Indivior(INDV.US) With Buy Rating, Announces Target Price $16
Indivior Initiated With a Buy at Rodman & Renshaw
Jefferies Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $15.16
Jefferies Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $24.41
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Indivior (INDV)
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $16
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Raises Target Price to $16
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Indivior (GB:INDV), Vor Biopharma (VOR) and Allogene Therapeutics (ALLO)
Unlock the Full List